U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chinnadurai S, Snyder K, Sathe N, et al. Diagnosis and Management of Infantile Hemangioma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. (Comparative Effectiveness Reviews, No. 168.)

Cover of Diagnosis and Management of Infantile Hemangioma

Diagnosis and Management of Infantile Hemangioma [Internet].

Show details

References

1.
Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015 Jul;136(1):e203–14. [PubMed: 26055853]
2.
Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008 Mar–Apr;25(2):168–73. [PubMed: 18429772]
3.
Hoornweg MJ, Smeulders MJ, van der Horst CM. [Prevalence and characteristics of haemangiomas in young children]. Ned Tijdschr Geneeskd. 2005 Oct 29;149(44):2455–8. [PubMed: 16285361]
4.
Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics. 1976 Aug;58(2):218–22. [PubMed: 951136]
5.
Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010 Nov;157(5):795–801.e1–7. [PubMed: 20598318]
6.
Christison-Lagay ER, Burrows PE, Alomari A, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg. 2007 Jan;42(1):62–7. discussion 7–8. [PubMed: 17208542]
7.
Stockman A, Boralevi F, Taieb A, et al. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology. 2007;214(1):40–5. [PubMed: 17191046]
8.
Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol. 1993 Dec;10(4):311–3. [PubMed: 8302734]
9.
Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008 Aug;122(2):360–7. [PubMed: 18676554]
10.
Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol. 2004 Jan–Feb;21(1):1–9. [PubMed: 14871317]
11.
Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol. 2001 Jun;44(6):962–72. [PubMed: 11369908]
12.
Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr. 2007 Dec;151(6):684–9. 9.e1. [PubMed: 18035154]
13.
Hartemink DA, Chiu YE, Drolet BA, et al. PHACES syndrome: a review. Int J Pediatr Otorhinolaryngol. 2009 Feb;73(2):181–7. [PubMed: 19101041]
14.
Tawfik AA, Alsharnoubi J. Topical Timolol Solution Versus Laser in Treatment of Infantile Hemangioma: A Comparative Study. Pediatr Dermatol. 2015 Mar 5 [PubMed: 25740672]
15.
Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013 Jan;131(1):128–40. [PMC free article: PMC3529954] [PubMed: 23266923]
16.
Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009 Sep;124(3):e423–31. [PubMed: 19706583]
17.
Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011 Aug;128(2):e259–66. [PubMed: 21788220]
18.
Georgountzou A, Karavitakis E, Klimentopoulou A, et al. Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. Acta Paediatr. 2012 Oct;101(10):e469–74. [PubMed: 22804809]
19.
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008 Jun 12;358(24):2649–51. [PubMed: 18550886]
20.
Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol. 1997 May–Jun;19(3):237–44. [PubMed: 9201147]
21.
Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol. 2000 Jul;136(7):905–14. [PubMed: 10890993]
22.
Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and management of infantile hemangioma. Pediatrics. 2015. in press. [PubMed: 26416928]
23.
Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; Jan, 2014. AHRQ Publication No. 10(14)-EHC063-EF. Chapters available at: www​.effectivehealthcare.ahrq.gov.
24.
Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982 Mar;69(3):412–22. [PubMed: 7063565]
25.
Viswanathan M, Ansari MT, Berkman ND, et al. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): 2008. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions.
26.
Wells G, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at http://www​.ohri.ca/programs​/clinical_epidemiology/oxford.asp.
27.
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011 Oct 18;155(8):529–36. [PubMed: 22007046]
28.
McMaster Centre for Evidence-based Practice. McMaster Quality Assessment Scale of Harms (McHarm) for primary studies. Hamilton ON: McMaster University; 2008.
29.
Berkman ND, Lohr KN, Ansari MT, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 2014 Dec 20 [PubMed: 25721570]
30.
Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol. 2002 Dec;138(12):1567–76. [PubMed: 12472344]
31.
Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006 Sep;118(3):882–7. [PubMed: 16950977]
32.
Li J, Chen X, Zhao S, et al. Demographic and clinical characteristics and risk factors for infantile hemangioma: a Chinese case-control study. Arch Dermatol. 2011 Sep;147(9):1049–56. [PubMed: 21576550]
33.
Stier MF, Glick SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. J Am Acad Dermatol. 2008 Feb;58(2):261–85. [PubMed: 18068263]
34.
Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003 Apr;48(4):477–93. quiz 94–6. [PubMed: 12664009]
35.
Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg. 1983 Dec;18(6):894–900. [PubMed: 6663421]
36.
Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents’ photographs tell us. Pediatrics. 2012 Aug;130(2):e314–20. [PubMed: 22826568]
37.
Brandling-Bennett HA, Metry DW, Baselga E, et al. Infantile hemangiomas with unusually prolonged growth phase: a case series. Arch Dermatol. 2008 Dec;144(12):1632–7. [PubMed: 19075148]
38.
Couto RA, Maclellan RA, Zurakowski D, et al. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg. 2012 Sep;130(3):619–24. [PubMed: 22575857]
39.
Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013 Jan;131(1):99–108. [PubMed: 23266916]
40.
Akyuz C, Yaris N, Kutluk MT, et al. Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Pediatr Hematol Oncol. 2001 Jan–Feb;18(1):47–55. [PubMed: 11205840]
41.
Sundine MJ, Wirth GA. Hemangiomas: an overview. Clin Pediatr (Phila). 2007 Apr;46(3):206–21. [PubMed: 17416876]
42.
Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. Archives of Dermatology. 1960;82(5):667–80.
43.
Liang MG, Frieden IJ. Infantile and congenital hemangiomas. Semin Pediatr Surg. 2014 Aug;23(4):162–7. [PubMed: 25241092]
44.
Jacobs AH. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med. 1957 Jan;86(1):8–10. [PMC free article: PMC1512000] [PubMed: 13383382]
45.
Bauland CG, Luning TH, Smit JM, et al. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg. 2011 Apr;127(4):1643–8. [PubMed: 21460670]
46.
Enjolras O, Riche MC, Merland JJ, et al. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990 Apr;85(4):491–8. [PubMed: 2097998]
47.
Luu M, Frieden IJ. Haemangioma: clinical course, complications and management. Br J Dermatol. 2013 Jul;169(1):20–30. [PubMed: 23701395]
48.
Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg. 2010 Jun;29(2):106–14. [PubMed: 20579599]
49.
Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol. 1997 Oct;37(4):631–7. [PubMed: 9344205]
50.
Bauland CG, Smit JM, Ketelaars R, et al. Management of haemangiomas of infancy: a retrospective analysis and a treatment protocol. Scand J Plast Reconstr Surg Hand Surg. 2008;42(2):86–91. [PubMed: 18335352]
51.
Lee AH, Hardy KL, Goltsman D, et al. A retrospective study to classify surgical indications for infantile hemangiomas. J Plast Reconstr Aesthet Surg. 2014 Sep;67(9):1215–21. [PMC free article: PMC4125502] [PubMed: 24923525]
52.
Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7–9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 2005 Sep–Oct;22(5):383–406. [PubMed: 16190987]
53.
Cohen-Barak E, Rozenman D, Shani Adir A. Infantile haemangiomas and quality of life. Arch Dis Child. 2013 Sep;98(9):676–9. [PubMed: 23864355]
54.
Hoornweg MJ, Grootenhuis MA, van der Horst CM. Health-related quality of life and impact of haemangiomas on children and their parents. J Plast Reconstr Aesthet Surg. 2009 Oct;62(10):1265–71. [PubMed: 18602360]
55.
Wananukul S. Clinical manifestation and management of hemangiomas of infancy. J Med Assoc Thai. 2002 Jun;85 Suppl 1:S280–5. [PubMed: 12188424]
56.
Pandey A, Gangopadhyay AN, Sharma SP, et al. Conservative management of ulcerated haemangioma--twenty years experience. Int Wound J. 2009 Feb;6(1):59–62. [PMC free article: PMC7951731] [PubMed: 19291117]
57.
Holland KE, Drolet BA. Approach to the patient with an infantile hemangioma. Dermatol Clin. 2013 Apr;31(2):289–301. [PubMed: 23557656]
58.
Gontijo B. Complications of infantile hemangiomas. Clin Dermatol. 2014 Jul–Aug;32(4):471–6. [PubMed: 25017458]
59.
Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006 Mar;117(3):698–703. [PubMed: 16510649]
60.
Muzaffar F. Clinical profile and morphologic types of infantile hemangioma. A study of 252 children. Journal of Pakistan Association of Dermatologists. 2005;15(2):119–24.
61.
Hermans DJ, Boezeman JB, Van de Kerkhof PC, et al. Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases. Eur J Dermatol. 2009 Mar–Apr;19(2):152–6. [PubMed: 19106042]
62.
Waner M, North PE, Scherer KA, et al. The nonrandom distribution of facial hemangiomas. Arch Dermatol. 2003 Jul;139(7):869–75. [PubMed: 12873881]
63.
Maguiness SM, Hoffman WY, McCalmont TH, et al. Early white discoloration of infantile hemangioma: a sign of impending ulceration. Arch Dermatol. 2010 Nov;146(11):1235–9. [PubMed: 21079059]
64.
Bramhall RJ, Quaba A. A review of 58 patients with periorbital haemangiomas to determine appropriate cases for intervention. J Plast Reconstr Aesthet Surg. 2008;61(2):138–49. [PubMed: 17981104]
65.
Schwartz SR, Blei F, Ceisler E, et al. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. J aapos. 2006 Jun;10(3):262–8. [PubMed: 16814181]
66.
Rahbar R, Nicollas R, Roger G, et al. The biology and management of subglottic hemangioma: past, present, future. Laryngoscope. 2004 Nov;114(11):1880–91. [PubMed: 15510009]
67.
Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution. J Pediatr. 1997 Oct;131(4):643–6. [PubMed: 9386676]
68.
Drolet BA, Chamlin SL, Garzon MC, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr. 2010 Nov;157(5):789–94. [PubMed: 20828712]
69.
Tubbs RS, Wellons JC 3rd, Iskandar BJ, et al. Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism. J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):86–9. [PubMed: 14758934]
70.
Kassarjian A, Zurakowski D, Dubois J, et al. Infantile hepatic hemangiomas: clinical and imaging findings and their correlation with therapy. AJR Am J Roentgenol. 2004 Mar;182(3):785–95. [PubMed: 14975986]
71.
Horii KA, Drolet BA, Frieden IJ, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol. 2011 May–Jun;28(3):245–53. [PubMed: 21517952]
72.
Dickie B, Dasgupta R, Nair R, et al. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg. 2009 Jan;44(1):125–33. [PubMed: 19159729]
73.
Metry DW, Haggstrom AN, Drolet BA, et al. A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. Am J Med Genet A. 2006 May 1;140(9):975–86. [PubMed: 16575892]
74.
Haggstrom AN, Garzon MC, Baselga E, et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010 Aug;126(2):e418–26. [PubMed: 20643720]
75.
Metry D, Frieden IJ, Hess C, et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol. 2013 Jan–Feb;30(1):71–89. [PMC free article: PMC4995066] [PubMed: 22994362]
76.
Fawcett SL, Grant I, Hall PN, et al. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg. 2004 Mar;57(2):168–71. [PubMed: 15037175]
77.
Puttgen KB. Diagnosis and management of infantile hemangiomas. Pediatr Clin North Am. 2014 Apr;61(2):383–402. [PubMed: 24636652]
78.
Canty KM, Horii KA, Ahmad H, et al. Multiple cutaneous and hepatic hemangiomas in infants. South Med J. 2014 Mar;107(3):159–64. [PubMed: 24937333]
79.
Hughes JA, Hill V, Patel K, et al. Cutaneous haemangioma: prevalence and sonographic characteristics of associated hepatic haemangioma. Clin Radiol. 2004 Mar;59(3):273–80. [PubMed: 15037141]
80.
Mai HM, Zheng JW, Wang YA, et al. CD133 selected stem cells from proliferating infantile hemangioma and establishment of an in vivo mice model of hemangioma. Chin Med J (Engl). 2013 Jan;126(1):88–94. [PubMed: 23286484]
81.
Boon LM, Burrows PE, Paltiel HJ, et al. Hepatic vascular anomalies in infancy: a twenty-seven-year experience. J Pediatr. 1996 Sep;129(3):346–54. [PubMed: 8804322]
82.
Vredenborg AD, Janmohamed SR, de Laat PC, et al. Multiple cutaneous infantile haemangiomas and the risk of internal haemangioma. Br J Dermatol. 2013 Jul;169(1):188–91. [PubMed: 23421718]
83.
Iyer CP, Stanley P, Mahour GH. Hepatic hemangiomas in infants and children: a review of 30 cases. Am Surg. 1996 May;62(5):356–60. [PubMed: 8615561]
84.
Stanley P, Geer GD, Miller JH, et al. Infantile hepatic hemangiomas. Clinical features, radiologic investigations, and treatment of 20 patients. Cancer. 1989 Aug 15;64(4):936–49. [PubMed: 2663135]
85.
Lopriore E, Markhorst DG. Diffuse neonatal haemangiomatosis: new views on diagnostic criteria and prognosis. Acta Paediatr. 1999 Jan;88(1):93–7. [PubMed: 10090556]
86.
Berman B, Lim H. Concurrent cutaneous and hepatic hemangiomata in infancy: report of a case and a review of the literature. J Dermatol Surg Oncol. 1978 Nov;4(11):869–73. [PubMed: 711970]
87.
Blei F, Guarini A. Current workup and therapy of infantile hemangiomas. Clin Dermatol. 2014 Jul–Aug;32(4):459–70. [PubMed: 25017457]
88.
TM O, Alexander RE, Lando T, et al. Segmental hemangiomas of the upper airway. Laryngoscope. 2009 Nov;119(11):2242–7. [PubMed: 19806648]
89.
TM O, Scheuermann-Poley C, Tan M, et al. Distribution, clinical characteristics, and surgical treatment of lip infantile hemangiomas. JAMA Facial Plast Surg. 2013 Jul–Aug;15(4):292–304. [PubMed: 23752875]
90.
Sherrington CA, Sim DK, Freezer NJ, et al. Subglottic haemangioma. Arch Dis Child. 1997 May;76(5):458–9. [PMC free article: PMC1717188] [PubMed: 9196368]
91.
Vlastarakos PV, Papacharalampous GX, Chrysostomou M, et al. Propranolol is an effective treatment for airway haemangiomas: a critical analysis and meta-analysis of published interventional studies. Acta Otorhinolaryngol Ital. 2012 Aug;32(4):213–21. [PMC free article: PMC3468939] [PubMed: 23093810]
92.
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–46. [PubMed: 25693013]
93.
Zaher H, Rasheed H, Esmat S, et al. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. Eur J Dermatol. 2013 Sep–Oct;23(5):646–52. [PubMed: 24135427]
94.
Sondhi V, Patnaik SK. Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. J Pediatr Hematol Oncol. 2013 Oct;35(7):493–9. [PubMed: 23929318]
95.
Thayal PK, Bhandari PS, Sarin YK. Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas. Plast Reconstr Surg. 2012 Apr;129(4):733e–5e. [PubMed: 22456397]
96.
Bertrand J, McCuaig C, Dubois J, et al. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatr Dermatol. 2011 Nov–Dec;28(6):649–54. [PubMed: 21995756]
97.
Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011 Dec;147(12):1371–6. [PubMed: 21844428]
98.
Bauman NM, McCarter RJ, Guzzetta PC, et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):323–30. [PubMed: 24526257]
99.
Leaute-Labreze C, Dumas de la Roque E, Nacka F, et al. Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age. Br J Dermatol. 2013 Jul;169(1):181–3. [PubMed: 23301692]
100.
Malik MA, Menon P, Rao KL, et al. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg. 2013 Dec;48(12):2453–9. [PubMed: 24314186]
101.
Pope E, Chakkittakandiyil A, Lara-Corrales I, et al. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013 Jan;168(1):222–4. [PubMed: 22762503]
102.
Abarzua-Araya A, Navarrete-Dechent CP, Heusser F, et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol. 2014 Jun;70(6):1045–9. [PubMed: 24656727]
103.
Yu L, Li S, Su B, et al. Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants. Exp Ther Med. 2013 August;6(2):388–90. [PMC free article: PMC3786899] [PubMed: 24137194]
104.
Chan H, McKay C, Adams S, et al. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics. 2013 Jun;131(6):e1739–47. [PubMed: 23650294]
105.
Qiu Y, Ma G, Yang J, et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study. Clin Exp Dermatol. 2013 Dec;38(8):845–50. [PubMed: 23627540]
106.
Park KH, Jang YH, Chung HY, et al. Topical timolol maleate 0.5% for infantile hemangioma; it’s effectiveness and/or adjunctive pulsed dye laser - single center experience of 102 cases in Korea. J Dermatolog Treat. 2014 Dec 29:1–3. [PubMed: 25424048]
107.
Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics. 2007 Jun;119(6):e1239–47. [PubMed: 17485449]
108.
Jalil S, Akhtar J, Ahmed S. Corticosteroids therapy in the management of infantile cutaneous hemangiomas. J Coll Physicians Surg Pak. 2006 Oct;16(10):662–5. [PubMed: 17007757]
109.
Gangopadhyay AN, Sharma SP, Gopal SC, et al. Local steroid therapy in cutaneous hemangiomas. Indian Pediatr. 1996 Jan;33(1):31–3. [PubMed: 8772948]
110.
Chowdri NA, Darzi MA, Fazili Z, et al. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. Ann Plast Surg. 1994 Jul;33(1):46–51. [PubMed: 7944196]
111.
Morrell AJ, Willshaw HE. Normalisation of refractive error after steroid injection for adnexal haemangiomas. Br J Ophthalmol. 1991 May;75(5):301–5. [PMC free article: PMC1042360] [PubMed: 2036349]
112.
Sloan GM, Reinisch JF, Nichter LS, et al. Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg. 1989 Mar;83(3):459–67. [PubMed: 2919200]
113.
Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plast Reconstr Surg. 2011 Sep;128(3):743–52. [PubMed: 21572374]
114.
Chantharatanapiboon W. Intralesional corticosteroid therapy in hemangiomas: clinical outcome in 160 cases. J Med Assoc Thai. 2008 Oct;91 Suppl 3:S90–6. [PubMed: 19253502]
115.
Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg. 2000 Mar;35(3):420–3. [PubMed: 10726680]
116.
Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999 Nov;104(6):1616–23. [PubMed: 10541160]
117.
Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr. 1996 Jan;128(1):141–6. [PubMed: 8551406]
118.
Kushner BJ. The treatment of periorbital infantile hemangioma with intralesional corticosteroid. Plast Reconstr Surg. 1985 Oct;76(4):517–26. [PubMed: 4034770]
119.
Sharma LK, Dalal SS. Corticosteroid therapy in the treatment of cutaneous hemangioma of infancy and childhood. Indian J Pediatr. 1983 Mar–Apr;50(403):153–6. [PubMed: 6618575]
120.
Pandey A, Gangopadhyay AN, Gopal SC, et al. Twenty years’ experience of steroids in infantile hemangioma--a developing country’s perspective. J Pediatr Surg. 2009 Apr;44(4):688–94. [PubMed: 19361627]
121.
Janmohamed SR, Madern GC, Nieuwenhuis K, et al. Evaluation of intra-lesional corticosteroids in the treatment of periocular haemangioma of infancy: still an alternative besides propranolol. Pediatr Surg Int. 2012 Apr;28(4):393–8. [PMC free article: PMC3311867] [PubMed: 22200732]
122.
Pandey A, Gangopadhyay AN, Sharma SP, et al. Evaluation of topical steroids in the treatment of superficial hemangioma. Skinmed. 2010 Jan–Feb;8(1):9–11. [PubMed: 20839418]
123.
Couto JA, Greene AK. Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. J Plast Reconstr Aesthet Surg. 2014 Nov;67(11):1469–74. [PubMed: 25104131]
124.
Ke Y, Hao R, He Y, et al. The value of color Doppler imaging and intralesional steroid injection in pediatric orbital capillary hemangioma. J Chin Med Assoc. 2014 May;77(5):258–64. [PubMed: 24694673]
125.
Saleh KH. Steroids in complicated hemangioma. Iranian Red Crescent Medical Journal. 2009;11(2):217.
126.
Kushner BJ. Infantile orbital hemangiomas. International Pediatrics. 1990;5(3):249–57.
127.
Garzon MC, Lucky AW, Hawrot A, et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol. 2005 Feb;52(2):281–6. [PubMed: 15692474]
128.
Samimi DB, Alabiad CR, Tse DT. An anatomically based approach to intralesional corticosteroid injection for eyelid capillary hemangiomas. Ophthalmic Surg Lasers Imaging. 2012 May–Jun;43(3):190–5. [PubMed: 22432604]
129.
Blei F, Chianese J. Corticosteroid toxicity in infants treated for endangering hemangiomas: experience and guidelines for monitoring. International Pediatrics. 1999;14:146–53.
130.
Awadein A, Fakhry MA. Evaluation of intralesional propranolol for periocular capillary hemangioma. Clin Ophthalmol. 2011;5(1):1135–40. [PMC free article: PMC3162293] [PubMed: 21887095]
131.
Hoornweg MJ, Saeed P, Tanck MW, et al. Comparison of intralesional corticosteroid and propranolol treatment of periorbital infantile hemangiomas: an outcome study of 61 cases. Eur J Ophthalmol. 2014 Nov–Dec;24(6):940–7. [PubMed: 24729139]
132.
Rossler J, Schill T, Bahr A, et al. Propranolol for proliferating infantile haemangioma is superior to corticosteroid therapy--a retrospective, single centre study. J Eur Acad Dermatol Venereol. 2012 Sep;26(9):1173–5. [PubMed: 22035186]
133.
Rossler J, Wehl G, Niemeyer CM. Evaluating systemic prednisone therapy for proliferating haemangioma in infancy. Eur J Pediatr. 2008 Jul;167(7):813–5. [PubMed: 17676341]
134.
Flo-Pred [package insert]. Hawthorne, NY: Taro Pharmaceuticals U.S.A., Inc.; 2011.
135.
Orapred ODT [package insert]. Bridgetown, Barbados: Concordia Pharmaceuticals Inc.; 2013.
136.
Rayos [package insert]. Deerfield, IL: Horizon Pharma Inc.; 2014.
137.
Depo-Medrol [package insert]. New York, NY: Pharmacia and Upjohn Co.; 2014.
138.
Solu-Medrol [package insert]. New York, NY: Pharmacia & Upjohn Co.; 2014.
139.
Celestone Soluspan [package insert]. Whitehouse Station, NJ: Merck Sharp Dohme; 2015.
140.
Medrol [package insert]. New York, NY: Pharmacia and Upjohn Company; 2013.
141.
Aristospan [package insert]. Princeton, NJ: Sandoz Inc; 2014.
142.
Kenalog-10 [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
143.
Elocon [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2012.
144.
Chambers CB, Katowitz WR, Katowitz JA, et al. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthal Plast Reconstr Surg. 2012 Mar–Apr;28(2):103–6. [PubMed: 22410658]
145.
Hermans DJ, van Beynum IM, Schultze Kool LJ, et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol. 2011 May;64(5):833–8. [PubMed: 21353329]
146.
de Graaf M, Raphael MF, Breugem CC, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. J Plast Reconstr Aesthet Surg. 2013 Dec;66(12):1732–40. [PubMed: 24011909]
147.
De Graaf M, Araphael M, Breugem C, et al. Treatment of infantile hemangiomas with atenolol or propranolol: Cohort study with historical control group. European Journal of Pediatric Dermatology. 2012 March;22(1):12.
148.
de Graaf M, Breur JM, Raphael MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol. 2011 Aug;65(2):320–7. [PubMed: 21601311]
149.
Perkins JA, Chen BS, Saltzman B, et al. Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures. JAMA Otolaryngol Head Neck Surg. 2014 Mar;140(3):220–7. [PubMed: 24557492]
150.
Reddy KK, Blei F, Brauer JA, et al. Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. Dermatol Surg. 2013 Jun;39(6):923–33. [PubMed: 23458381]
151.
Xiao Q, Li Q, Zhang B, et al. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. Pediatr Surg Int. 2013 Jun;29(6):575–81. [PMC free article: PMC3657346] [PubMed: 23519547]
152.
Hassan BA, Shreef KS. Propranolol in treatment of huge and complicated infantile hemangiomas in egyptian children. Dermatol Res Pract. 2014;2014(541810) [PMC free article: PMC4034713] [PubMed: 24899888]
153.
Szychta P, Stewart K, Anderson W. Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg. 2014 Apr;133(4):852–62. [PubMed: 24352207]
154.
Vercellino N, Romanini MV, Pelegrini M, et al. The use of propranolol for complicated infantile hemangiomas. Int J Dermatol. 2013 Sep;52(9):1140–6. [PubMed: 23829783]
155.
Yuan WL, Jin ZL, Wei JJ, et al. Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. Br J Oral Maxillofac Surg. 2013 Oct;51(7):656–61. [PubMed: 23291092]
156.
Talaat AA, Elbasiouny MS, Elgendy DS, et al. Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations. J Pediatr Surg. 2012 Apr;47(4):707–14. [PubMed: 22498385]
157.
Zaher H, Rasheed H, Hegazy RA, et al. Oral propranolol: an effective, safe treatment for infantile hemangiomas. Eur J Dermatol. 2011 Jul–Aug;21(4):558–63. [PubMed: 21697036]
158.
Holmes WJ, Mishra A, Gorst C, et al. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2011 Apr;64(4):445–51. [PubMed: 20797926]
159.
Semkova K, Kazandjieva J. Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study. Clin Exp Dermatol. 2013 Mar;38(2):143–6. [PubMed: 22731954]
160.
Bonifazi E, Milano A, Colonna V. Evaluation of safety and efficacy of a galenic preparation of 1% propranolol in 89 cases of cutaneous infantile hemangioma. European Journal of Pediatric Dermatology. 2013 April–June;23(2):93–104.
161.
Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012 Jan–Feb;29(1):28–31. [PubMed: 22150436]
162.
Snir M, Reich U, Siegel R, et al. Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol. Eye (Lond). 2011 Dec;25(12):1627–34. [PMC free article: PMC3234475] [PubMed: 21921959]
163.
Jian D, Chen X, Babajee K, et al. Adverse effects of propranolol treatment for infantile hemangiomas in China. J Dermatolog Treat. 2014 Oct;25(5):388–90. [PubMed: 23216314]
164.
Bertrand J, Sammour R, McCuaig C, et al. Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic. J Cutan Med Surg. 2012 Sep–Oct;16(5):317–23. [PubMed: 22971306]
165.
Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol. 2011 Mar–Apr;28(2):94–8. [PubMed: 21362031]
166.
Saint-Jean M, Leaute-Labreze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol. 2011 May;64(5):827–32. [PubMed: 21353332]
167.
Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 2011 Apr;170(4):493–501. [PubMed: 20936416]
168.
Puttgen KB, Summerer B, Schneider J, et al. Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. Ann Otol Rhinol Laryngol. 2013 Sep;122(9):550–4. [PubMed: 24224397]
169.
Liu LS, Sokoloff D, Antaya RJ. Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas--is it indicated? Pediatr Dermatol. 2013 Sep–Oct;30(5):554–60. [PubMed: 23829941]
170.
Hong P, Tammareddi N, Walvekar R, et al. Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age. Int J Pediatr Otorhinolaryngol. 2013 Jul;77(7):1194–7. [PubMed: 23706952]
171.
Ma X, Zhao T, Xiao Y, et al. Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. Eur J Pediatr. 2013 May;172(5):653–9. [PubMed: 23340697]
172.
Hermans DJ, Bauland CG, Zweegers J, et al. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. Br J Dermatol. 2013 Apr;168(4):837–43. [PubMed: 23278381]
173.
Park YW, Yeom KB, Choi JW, et al. Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience. J Dermatolog Treat. 2014 Oct;25(5):391–5. [PubMed: 23273264]
174.
Gan LQ, Ni SL, Tan Q, et al. A retrospective study of propranolol therapy in 109 infants with infantile hemangioma. Pediatr Dermatol. 2013 Mar–Apr;30(2):270–2. [PubMed: 23252446]
175.
Phillips RJ, Penington AJ, Bekhor PS, et al. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health. 2012 Oct;48(10):902–6. [PubMed: 22897120]
176.
Zegpi-Trueba MS, Abarzua-Araya A, Silva-Valenzuela S, et al. Oral propranolol for treating infantile hemangiomas: a case series of 57 patients. Actas Dermosifiliogr. 2012 Oct;103(8):708–17. [PubMed: 22853960]
177.
Celik A, Tiryaki S, Musayev A, et al. Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers. J Drugs Dermatol. 2012 Jul;11(7):808–11. [PubMed: 22777220]
178.
Balma-Mena A, Chakkittakandiyil A, Weinstein M, et al. Propranolol in the management of infantile hemangiomas: clinical response and predictors. J Cutan Med Surg. 2012 May–Jun;16(3):169–73. [PubMed: 22713439]
179.
Lv MM, Fan XD, Su LX. Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. Int J Pediatr Otorhinolaryngol. 2012 Apr;76(4):574–8. [PubMed: 22326207]
180.
Schupp CJ, Kleber JB, Gunther P, et al. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol. 2011 Nov–Dec;28(6):640–4. [PubMed: 21995836]
181.
Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg. 2011 May;137(5):471–8. [PubMed: 21576558]
182.
Cushing SL, Boucek RJ, Manning SC, et al. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg. 2011 Jan;144(1):78–84. [PubMed: 21493392]
183.
Sadykov RR, Podmelle F, Sadykov RA, et al. Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region. Int J Oral Maxillofac Surg. 2013 Jul;42(7):863–7. [PubMed: 23618833]
184.
Bagazgoitia L, Torrelo A, Gutierrez JC, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011 Mar–Apr;28(2):108–14. [PubMed: 21385205]
185.
Blatt J, Morrell DS, Buck S, et al. beta-blockers for infantile hemangiomas: a single-institution experience. Clin Pediatr (Phila). 2011 Aug;50(8):757–63. [PubMed: 21525081]
186.
Xu G, Lv R, Zhao Z, et al. Topical propranolol for treatment of superficial infantile hemangiomas. J Am Acad Dermatol. 2012 Dec;67(6):1210–3. [PubMed: 22516113]
187.
Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2012 Mar–Apr;29(2):154–9. [PubMed: 22141326]
188.
Raphael MF, Breugem CC, Vlasveld FA, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study. J Am Acad Dermatol. 2015 Mar;72(3):465–72. [PubMed: 25592625]
189.
Xu DP, Cao RY, Xue L, et al. Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. J Oral Maxillofac Surg. 2015 Mar;73(3):430–6. [PubMed: 25544304]
190.
Solman L, Murabit A, Gnarra M, et al. Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. Arch Dis Child. 2014 Dec;99(12):1132–6. [PubMed: 25123404]
191.
El Ezzi O, Hohlfeld J, de Buys Roessingh A. Propranolol in infantile haemangioma: simplifying pretreatment monitoring. Swiss Med Wkly. 2014;144:w13943. [PubMed: 24610228]
192.
Sagi L, Zvulunov A, Lapidoth M, et al. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. Dermatology. 2014;228(2):136–44. [PubMed: 24556822]
193.
Andersen IG, Rechnitzer C, Charabi B. Effectiveness of propanolol for treatment of infantile haemangioma. Dan Med J. 2014 Feb;61(2):A4776. [PubMed: 24495884]
194.
Lynch M, Lenane P, O’Donnell BF. Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients. Clin Exp Dermatol. 2014 Mar;39(2):142–5. [PubMed: 24289272]
195.
Giachetti A, Garcia-Monaco R, Sojo M, et al. Long-term treatment with oral propranolol reduces relapses of infantile hemangiomas. Pediatr Dermatol. 2014 Jan–Feb;31(1):14–20. [PubMed: 24283619]
196.
May JE, Liew SH. A new treatment pathway for propranolol use in infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2014 Mar;67(3):e91–2. [PubMed: 24268691]
197.
Wang L, Xia Y, Zhai Y, et al. Topical propranolol hydrochloride gel for superficial infantile hemangiomas. J Huazhong Univ Sci Technolog Med Sci. 2012 Dec;32(6):923–6. [PubMed: 23271298]
198.
Chen ZG, Zheng JW, Yuan ML, et al. A novel topical nano-propranolol for treatment of infantile hemangiomas. Nanomedicine. 2015 Mar 16 [PubMed: 25791814]
199.
Chu DH, Castelo-Soccio L, Wan J, et al. Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study). Clin Pediatr (Phila). 2014 Oct;53(11):1084–90. [PMC free article: PMC4312282] [PubMed: 24849505]
200.
Schneider M, Cremer HJ, Ruef P. A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. Acta Paediatr. 2014 Sep;103(9):977–83. [PubMed: 24837972]
201.
Chai Q, Chen WL, Huang ZQ, et al. Preliminary experiences in treating infantile hemangioma with propranolol. Ann Plast Surg. 2014 Feb;72(2):169–72. [PubMed: 21629056]
202.
Muzaffar F, Shah GN. Propranolol for the treatment of infantile hemangioma: Our experience at The Children’s Hospital, Lahore. Journal of Pakistan Association of Dermatologists. 2014;24(4):312–8.
203.
Martinez Roca C, Rodriguez Ruiz M, Vilaboa Pedrosa C, et al. Oral propranolol in the treatment of infantile hemangioma: A case series of 50 infants. European Journal of Pediatric Dermatology. 2014 April–June;24(2):86–90.
204.
Schneider M, Reimer A, Cremer H, et al. Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas. World J Pediatr. 2014 Nov;10(4):313–7. [PubMed: 25515804]
205.
Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010 Feb 1;162(2):466–8. [PubMed: 20055816]
206.
Hemangeol [package insert]. Parsippany, NJ: Pierre Fabre Pharmaceuticals, Inc.; 2014.
207.
Propranolol Hydrochloride Solution [package insert]. Columbus, OH: Roxane Laboratories, Inc; 2012.
208.
Inderal LA [package insert]. Cranford, NJ: Akrimax Pharmaceuticals, LLC; 2012.
209.
Propranolol Hydrochloride Tablet [package insert]. Eatontown, NJ: Heritage Pharmaceuticals Inc.; 2013.
210.
Kessels JP, Hamers ET, Ostertag JU. Superficial hemangioma: pulsed dye laser versus wait-and-see. Dermatol Surg. 2013 Mar;39(3 Pt 1):414–21. [PubMed: 23279058]
211.
Kono T, Sakurai H, Groff WF, et al. Comparison study of a traditional pulsed dye laser versus a long-pulsed dye laser in the treatment of early childhood hemangiomas. Lasers Surg Med. 2006 Feb;38(2):112–5. [PubMed: 16374781]
212.
Batta K, Goodyear HM, Moss C, et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet. 2002 Aug 17;360(9332):521–7. [PubMed: 12241656]
213.
Tay YK, Tan SK. Treatment of infantile hemangiomas with the 595-nm pulsed dye laser using different pulse widths in an Asian population. Lasers Surg Med. 2012 Feb;44(2):93–6. [PubMed: 22241650]
214.
Nicolai T, Fischer-Truestedt C, Reiter K, et al. Subglottic hemangioma: a comparison of CO2 laser, Neodym-Yag laser, and tracheostomy. Pediatr Pulmonol. 2005 Mar;39(3):233–7. [PubMed: 15635618]
215.
Raulin C, Greve B. Retrospective clinical comparison of hemangioma treatment by flashlamp-pumped (585 nm) and frequency-doubled Nd:YAG (532 nm) lasers. Lasers Surg Med. 2001;28(1):40–3. [PubMed: 11430441]
216.
Chang CJ, Kelly KM, Nelson JS. Cryogen spray cooling and pulsed dye laser treatment of cutaneous hemangiomas. Ann Plast Surg. 2001 Jun;46(6):577–83. [PubMed: 11405354]
217.
Achauer BM, Vander Kam VM. Capillary hemangioma (strawberry mark) of infancy: comparison of argon and Nd:YAG laser treatment. Plast Reconstr Surg. 1989 Jul;84(1):60–9. discussion 70. [PubMed: 2734405]
218.
Vlachakis I, Arbiros I, Velaoras K, et al. Different modes cooling the epidermis with ice during Nd:YAG laser treatment of hemangiomas in children. Med Laser Appl. 2004 May;19(1):19–23.
219.
Ryzhevskiy DV, Trubin VV, Durnovo EA. The use of selective photothermolysis with sclerosing to treat congenital and neonatal vascular maxillofacial hyperplasia in children. Sovremennye Tehnologii v Medicine. 2014;6(4):145–9.
220.
Goelz R, Moll M, Meisner C, et al. Prospective controlled study to evaluate cryocontact therapy for infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2014 Jul;99(4):F345–6. [PubMed: 24668831]
221.
Li DN, Gold MH, Sun ZS, et al. Treatment of infantile hemangioma with optimal pulse technology. J Cosmet Laser Ther. 2010 Jun;12(3):145–50. [PubMed: 20482239]
222.
David LR, Malek MM, Argenta LC. Efficacy of pulse dye laser therapy for the treatment of ulcerated haemangiomas: a review of 78 patients. Br J Plast Surg. 2003 Jun;56(4):317–27. [PubMed: 12873458]
223.
Kwon SH, Choi JW, Byun SY, et al. Effect of early long-pulse pulsed dye laser treatment in infantile hemangiomas. Dermatol Surg. 2014 Apr;40(4):405–11. [PubMed: 24460784]
224.
Rizzo C, Brightman L, Chapas AM, et al. Outcomes of childhood hemangiomas treated with the pulsed-dye laser with dynamic cooling: a retrospective chart analysis. Dermatol Surg. 2009 Dec;35(12):1947–54. [PubMed: 19889007]
225.
Poetke M, Philipp C, Berlien HP. Flashlamp-pumped pulsed dye laser for hemangiomas in infancy: treatment of superficial vs mixed hemangiomas. Arch Dermatol. 2000 May;136(5):628–32. [PubMed: 10815856]
226.
Morelli JG, Tan OT, Yohn JJ, et al. Treatment of ulcerated hemangiomas infancy. Arch Pediatr Adolesc Med. 1994 Oct;148(10):1104–5. [PubMed: 7921107]
227.
Di Maio L, Baldi A, Dimaio V, et al. Use of flashlamp-pumped pulsed dye laser in the treatment of superficial vascular malformations and ulcerated hemangiomas. In Vivo. 2011 Jan–Feb;25(1):117–23. [PubMed: 21282744]
228.
Chen W, Liu S, Yang C, et al. Clinical efficacy of the 595 nm pulsed dye laser in the treatment of childhood superficial hemangioma - analysis of 10-year application in Chinese patients. J Dermatolog Treat. 2015 Feb;26(1):54–8. [PubMed: 23697537]
229.
Hohenleutner S, Badur-Ganter E, Landthaler M, et al. Long-term results in the treatment of childhood hemangioma with the flashlamp-pumped pulsed dye laser: an evaluation of 617 cases. Lasers Surg Med. 2001;28(3):273–7. [PubMed: 11295764]
230.
Chen W, Yang C, Liu S, et al. Curative effect study of pulsed dye laser in the treatment of 43 patients with hand infantile hemangioma. Eur J Dermatol. 2014 Jan–Feb;24(1):76–9. [PubMed: 24413474]
231.
Preeyanont P, Nimsakul N. The Nd:YAG laser treatment of hemangioma. J Clin Laser Med Surg. 1994 Aug;12(4):225–9. [PubMed: 10147482]
232.
Chang CJ. Long term follow-up of intralesional laser photocoagulation (ILP) for hemangioma patients. Laser Therapy. 2011;20(4):255–63. [PMC free article: PMC3799045] [PubMed: 24155535]
233.
Waldschmidt J, Giest H, Meyer L. Endoscopic laser application in 56 children with hemangiomas of the larynx and trachea. Med Laser Appl. 2005 Aug Dec;20(4):297–302.
234.
Vlachakis I, Gardikis S, Michailoudi E, et al. Treatment of hemangiomas in children using a Nd:YAG laser in conjunction with ice cooling of the epidermis: techniques and results. BMC Pediatr. 2003 Apr 12;3:2. [PMC free article: PMC155650] [PubMed: 12697072]
235.
Kaune KM, Lauerer P, Kietz S, et al. Combination therapy of infantile hemangiomas with pulsed dye laser and Nd:YAG laser is effective and safe. J Dtsch Dermatol Ges. 2014 Jun;12(6):473–8. [PubMed: 24825388]
236.
Su W, Ke Y, Xue J. Beneficial effects of early treatment of infantile hemangiomas with a long-pulse Alexandrite laser. Lasers Surg Med. 2014 Mar;46(3):173–9. [PubMed: 24391080]
237.
Healy G, McGill T, Friedman EM. Carbon dioxide laser in subglottic hemangioma. An update. Ann Otol Rhinol Laryngol. 1984 Jul–Aug;93(4 Pt 1):370–3. [PubMed: 6431866]
238.
Wu JK, Rohde CH. Purse-string closure of hemangiomas: early results of a follow-up study. Ann Plast Surg. 2009 May;62(5):581–5. [PubMed: 19387166]
239.
Chen W, Li J, Yang Z, et al. SMAS fold flap and ADM repair of the parotid bed following removal of parotid haemangiomas via pre- and retroauricular incisions to improve cosmetic outcome and prevent Frey’s syndrome. J Plast Reconstr Aesthet Surg. 2008 Aug;61(8):894–9. discussion 9–900. [PubMed: 18504166]
240.
Li WY, Chaudhry O, Reinisch JF. Guide to early surgical management of lip hemangiomas based on our experience of 214 cases. Plast Reconstr Surg. 2011 Nov;128(5):1117–24. [PubMed: 21738083]
241.
Kulbersh J, Hochman M. Serial excision of facial hemangiomas. Arch Facial Plast Surg. 2011 May–Jun;13(3):199–202. [PubMed: 21576667]
242.
Arneja JS, Mulliken JB. Resection of amblyogenic periocular hemangiomas: indications and outcomes. Plast Reconstr Surg. 2010 Jan;125(1):274–81. [PubMed: 20048618]
243.
Hamou C, Diner PA, Dalmonte P, et al. Nasal tip haemangiomas: guidelines for an early surgical approach. J Plast Reconstr Aesthet Surg. 2010 Jun;63(6):934–9. [PubMed: 19540825]
244.
Chen WL, Zhang B, Li JS, et al. Liquid nitrogen cryotherapy of lip mucosa hemangiomas under inhalation general anesthesia with sevoflurane in early infancy. Ann Plast Surg. 2009 Feb;62(2):154–7. [PubMed: 19158525]
245.
Claude O, Picard A, O’Sullivan N, et al. Use of ultrasonic dissection in the early surgical management of periorbital haemangiomas. J Plast Reconstr Aesthet Surg. 2008 Dec;61(12):1479–85. [PubMed: 18037085]
246.
McHeik JN, Renauld V, Duport G, et al. Surgical treatment of haemangioma in infants. Br J Plast Surg. 2005 Dec;58(8):1067–72. [PubMed: 16039624]
247.
Demiri EC, Pelissier P, Genin-Etcheberry T, et al. Treatment of facial haemangiomas: the present status of surgery. Br J Plast Surg. 2001 Dec;54(8):665–74. [PubMed: 11728108]
248.
Zide BM, Glat PM, Stile FL, et al. Vascular lip enlargement: Part I. Hemangiomas--tenets of therapy. Plast Reconstr Surg. 1997 Dec;100(7):1664–73. [PubMed: 9393462]
249.
Baraldini V, Coletti M, Cigognetti F, et al. Haemostatic squeezing and purse-string sutures: optimising surgical techniques for early excision of critical infantile haemangiomas. J Pediatr Surg. 2007 Feb;42(2):381–5. [PubMed: 17270553]
250.
Batta K, Goodyear H, Moss C, et al. Randomized controlled study of early pulsed dye laser treatment of uncomplicated infantile haemangiomas: results of a 5-year analysis. British Journal of Dermatology. 2008;159(Suppl 1):113.
251.
Daramola OO, Chun RH, Nash JJ, et al. Surgical treatment of infantile hemangioma in a multidisciplinary vascular anomalies clinic. Int J Pediatr Otorhinolaryngol. 2011 Oct;75(10):1271–4. [PubMed: 21803434]
252.
Murphy RK, Reynolds MR, Mansur DB, et al. Gamma knife surgery for a hemangioma of the cavernous sinus in a child. J Neurosurg Pediatr. 2013 Jan;11(1):74–8. [PubMed: 23082966]
253.
Xu SQ, Jia RB, Zhang W, et al. Beta-blockers versus corticosteroids in the treatment of infantile hemangioma: an evidence-based systematic review. World J Pediatr. 2013 Aug;9(3):221–9. [PubMed: 23929254]
254.
Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013 Mar;131(3):601–13. [PubMed: 23142941]
255.
Wat H, Wu DC, Rao J, et al. Application of intense pulsed light in the treatment of dermatologic disease: a systematic review. Dermatol Surg. 2014 Apr;40(4):359–77. [PubMed: 24495252]
256.
Prasetyono TO, Djoenaedi I. Efficacy of intralesional steroid injection in head and neck hemangioma: a systematic review. Ann Plast Surg. 2011 Jan;66(1):98–106. [PubMed: 21042190]
257.
Leonardi-Bee J, Batta K, O’Brien C, et al. Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. Cochrane Database Syst Rev. 2011;(5) [PubMed: 21563155]
258.
Gunturi N, Ramgopal S, Balagopal S, et al. Propranolol therapy for infantile hemangioma. Indian Pediatr. 2013 Mar;50(3):307–13. [PubMed: 23680605]
259.
Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013 Mar–Apr;30(2):182–91. [PubMed: 23405852]
260.
Peridis S, Pilgrim G, Athanasopoulos I, et al. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol. 2011 Apr;75(4):455–60. [PubMed: 21333364]
261.
Lou Y, Peng WJ, Cao Y, et al. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014 Jul;78(1):44–57. [PMC free article: PMC4168379] [PubMed: 24033819]
262.
Spiteri Cornish K, Reddy AR. The use of propranolol in the management of periocular capillary haemangioma--a systematic review. Eye (Lond). 2011 Oct;25(10):1277–83. [PMC free article: PMC3194317] [PubMed: 21738233]
263.
Mawn LA. Infantile hemangioma: treatment with surgery or steroids. Am Orthopt J. 2013;63:6–13. [PubMed: 24260801]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (3.7M)

Other titles in these collections

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...